Skip to Main Content

AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH

Conditions

Diseases of the Digestive System - Liver

Phase III

What is the purpose of this trial?

The AURORA study will be conducted to confirm the efficacy and safety of cenicriviroc (CVC) for the treatment of liver fibrosis in adult subjects with NASH.

  • Trial with
    Tobira Therapeutics
  • Start Date
    03/25/2018
  • End Date
    07/30/2019
Trial Image

For more information about this study, contact:

Hong Chau

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    06/05/2018
  • Study HIC
    #2000021152